文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

CALR突变骨髓增殖性肿瘤的疾病起始造血干细胞特征

Characterization of disease-initiating hematopoietic stem cells in calreticulin-mutated myeloproliferative neoplasms.
PubMed 文献 · Blood · 2026-09-25

该研究通过将CALRdel52和CALRins5敲入小鼠与Vwf-GFP报告小鼠杂交,发现CALR突变MPN主要起源于血小板偏向性Vwf阳性HSC的扩增,且CALRdel52比CALRins5有更强的HSC扩增。这种选择性扩增与MPL信号增强及PERK/eIF2a整合应激反应激活相关,药物抑制PERK可减少小鼠CALRdel52 HSC增殖并损害患者CALRdel52样HSPC的巨核分化,同时不伤害健康供者细胞。

要点

  • CALR突变MPN由血小板偏向性Vwf阳性HSC扩增启动,谱系偏向未明显改变。
  • CALRdel52较CALRins5的HSC选择性扩增与MPL信号增强及PERK/eIF2a通路激活相关。
  • PERK抑制可选择性抑制CALRdel52 HSC增殖和患者CALRdel52样HSPC巨核分化。

核心结论

  • CALR突变MPN主要起源于Vwf阳性血小板偏向性HSC的扩增,PERK/eIF2a通路是其机制弱点。

研究设计与样本

  • 将CALRdel52和CALRins5敲入小鼠与Vwf启动子驱动GFP的转基因报告小鼠杂交以区分HSC亚群。
  • 重新分析既往患者造血干祖细胞(HSPC)数据集并进行功能验证。

主要发现

  • CALRdel52小鼠较CALRins5小鼠有更强的HSC扩增,且扩增的HSC为Vwf阳性。
  • CALRdel52 HSC中MPL信号增强并激活PERK下游eIF2a磷酸化。
  • 该通路在CALRdel52样患者HSPC中转录上调并伴eIF2a磷酸化增加。
  • PERK药理抑制显著减少小鼠CALRdel52 HSC增殖。
  • PERK抑制损害患者CALRdel52样HSPC巨核分化而不影响健康供者细胞。

临床怎么用

  • PERK/eIF2a通路可作为CALR突变MPN起始细胞的潜在治疗靶点。
  • 需进一步探索PERK抑制剂在CALRdel52突变MPN中的治疗价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myeloproliferative neoplasms (MPNs) arise following the acquisition of a mutation in a hematopoietic stem cell (HSC) that causes oncogenic cytokine receptor signaling. Mutations in the calreticulin (CALR) gene are the second most common key driver mutations in MPNs, yet the identity of the disease-initiating HSCs and the mechanisms underlying their clonal expansion remain elusive. Knock-in mice bearing CALRdel52 and CALRins5 mutations recapitulate disease phenotypes, with a greater HSC amplification in CALRdel52 mice. Here, we crossed these strains with transgenic reporter mice expressing GFP under the control of the Von willebrand factor (Vwf) promoter, enabling discrimination between different HSC subsets. We show that CALR-mutated MPNs are mainly initiated from the expansion of platelet-biased, Vwf-positive HSCs, without substantially altering their lineage bias. Notably, the selective amplification of Vwf-positive CALRdel52 compared to CALRins5 HSCs is associated with increased signaling of the thrombopoietin receptor MPL and activation of the integrated stress response as evidenced by eIF2a phosphorylation downstream of PERK kinase triggered by endoplasmic reticulum stress. This pathway is also transcriptionally upregulated in CALRdel52-like compared with CALRins5-like patient hematopoietic stem and progenitor cells (HSPCs), as supported by reanalysis of a previous dataset, and is associated with increased phosphorylation of eIF2a. Pharmacological inhibition of PERK markedly reduces the proliferation of mouse CALRdel52 HSCs and impairs the megakaryocytic differentiation of CALRdel52-like HSPCs from patients while sparing cells from healthy donors. These findings identify the PERK/eIF2a pathway as a mechanistic vulnerability in the MPN cell-of-origin and offer a rationale for exploring new treatment approaches.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Benlabiod C, Borderon L, Hermange G, et al. Characterization of disease-initiating hematopoietic stem cells in calreticulin-mutated myeloproliferative neoplasms. Blood. 2026. PMID: 42789459. doi:10.1182/blood.2026033236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。